Universität zu Köln

Rossetti, Barbara, Fabbiani, Massimiliano ORCID: 0000-0002-1343-812X, Di Carlo, Domenico, Incardona, Francesca, Abecasis, Ana ORCID: 0000-0002-3903-5265, Gomes, Perpetua ORCID: 0000-0003-3271-8255, Geretti, Anna Maria, Seguin-Devaux, Carole ORCID: 0000-0003-0636-5222, Garcia, Federico, Kaiser, Rolf, Modica, Sara, Shallvari, Adrian, Sonnerborg, Anders and Zazzi, Maurizio ORCID: 0000-0002-0344-6281 (2022). Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe. HIV Med., 23 (7). S. 774 - 790. HOBOKEN: WILEY. ISSN 1468-1293

Full text not available from this repository.

Abstract

Objectives To explore the effectiveness and durability of integrase strand transfer inhibitor (INSTI)-based regimens in pre-treated subjects. Methods Treatment-experienced individuals starting an INSTI-based regimen during 2012-2019 were selected from the INTEGRATE collaborative study. The time to virological failure [VF: one measurement of viral load (VL) >= 1000 copies/mL or two >= 50 copies/ml or one VL measurement >= 50 copies/mL followed by treatment change] and to INSTI discontinuation were evaluated. Results Of 13 560 treatments analysed, 4284 were from INSTI-naive, non-viraemic (IN-NV) individuals, 1465 were from INSTI-naive, viraemic (IN-V) individuals, 6016 were from INSTI-experienced, non-viraemic (IE-NV) individuals and 1795 were from INSTI-experienced, viraemic (IE-V) individuals. Major INSTI drug resistance mutations (DRMs) were previously detected in 4/519 (0.8%) IN-NV, 3/394 (0.8%) IN-V, 7/1510 (0.5%) IE-NV and 25/935 (2.7%) IE-V individuals. The 1-year estimated probabilities of VF were 3.1% [95% confidence interval (CI): 2.5-3.8] in IN-NV, 18.4% (95% CI: 15.8-21.2) in IN-V, 4.2% (95% CI: 3.6-4.9) in IE-NV and 23.9% (95% CI: 20.9-26.9) in IE-V subjects. The 1-year estimated probabilities of INSTI discontinuation were 12.1% (95% CI: 11.1-13.0) in IN-NV, 19.6% (95% CI: 17.5-21.6) in IN-V, 10.8% (95% CI: 10.0-11.6) in IE-NV and 21.7% (95% CI: 19.7-23.5) in IE-V subjects. Conclusions Both VF and INSTI discontinuation occur at substantial rates in viraemic subjects. Detection of DRMs in a proportion of INSTI-experienced individuals makes INSTI resistance testing mandatory after failure.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Rossetti, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Fabbiani, Massimiliano UNSPECIFIED orcid.org/0000-0002-1343-812X UNSPECIFIED Di Carlo, Domenico UNSPECIFIED UNSPECIFIED UNSPECIFIED Incardona, Francesca UNSPECIFIED UNSPECIFIED UNSPECIFIED Abecasis, Ana UNSPECIFIED orcid.org/0000-0002-3903-5265 UNSPECIFIED Gomes, Perpetua UNSPECIFIED orcid.org/0000-0003-3271-8255 UNSPECIFIED Geretti, Anna Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Seguin-Devaux, Carole UNSPECIFIED orcid.org/0000-0003-0636-5222 UNSPECIFIED Garcia, Federico UNSPECIFIED UNSPECIFIED UNSPECIFIED Kaiser, Rolf UNSPECIFIED UNSPECIFIED UNSPECIFIED Modica, Sara UNSPECIFIED UNSPECIFIED UNSPECIFIED Shallvari, Adrian UNSPECIFIED UNSPECIFIED UNSPECIFIED Sonnerborg, Anders UNSPECIFIED UNSPECIFIED UNSPECIFIED Zazzi, Maurizio UNSPECIFIED orcid.org/0000-0002-0344-6281 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-694534
DOI:	10.1111/hiv.13262
Journal or Publication Title:	HIV Med.
Volume:	23
Number:	7
Page Range:	S. 774 - 790
Date:	2022
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1468-1293
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ANTIRETROVIRAL-NAIVE ADULTS; CO-FORMULATED ELVITEGRAVIR; ONCE-DAILY DOLUTEGRAVIR; NON-INFERIORITY; DOUBLE-BLIND; INITIAL TREATMENT; TENOFOVIR ALAFENAMIDE; OPEN-LABEL; THERAPY; EMTRICITABINE Multiple languages Infectious Diseases Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69453